Today is just another reason as to why buying and holding through FDA news is not worth it.
This company had good news (after years of delays) and still goes down.
I think this morning's news of debt financing is good for shareholders ...
But the risk to reward holding through is once again not positive. If it was poor news, you would expect it to drop 30-40%, so on positive news, you would expect more than a 30% rise.
Horrible to play through events .... Well, that's my experience.
Let's see if this can find support and bounce. That would make this interesting ...